510(k) Report

510(k) · Cleared

Cleared

Cedia Dau 6-Acetylmorphine Assay

K001178510(k) TraditionalCleared Jun 9, 200059-day reviewClass II21 CFR 862.3650

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Microgenics Corp. · DJG Enzyme Immunoassay, Opiates

Cleared on Jun 9, 2000 after a 59-day review. FDA has not posted a summary or statement for it, so its predicates are not known. 60 later devices descend from it.

Decided
Jun 9, 2000
Review
59 days
Class
Class II
Product code
DJG
Recalls
None
Predicates
0

60 later devices descend from it, 4 citing it directly.

Descendants, by year cleared 2010: 2 descendants cleared2011: 1 descendant cleared2004: 1 descendant cleared2017: 3 descendants cleared2014: 1 descendant cleared2008: 1 descendant cleared2015: 3 descendants cleared2005: 2 descendants cleared2019: 2 descendants cleared2006: 1 descendant cleared2013: 2 descendants cleared2009: 1 descendant cleared2023: 5 descendants cleared2007: 1 descendant cleared2026: 3 descendants cleared2018: 5 descendants cleared2016: 1 descendant cleared2022: 1 descendant cleared2020: 2 descendants cleared2025: 7 descendants cleared2024: 15 descendants cleared200020052010201520202025
  1. This deviceK001178 Cedia Dau 6-Acetylmorphine AssayMicrogenics Corp. · 2000
  2. Descendant · cites it directly · 52 of its ownK040316 Cedia Buprenorphine AssayMicrogenics Corp. · 2004
  3. Descendant · 2 generations on · 25 of its ownK150606 Emit II Plus Buprenorphine Assay, Emit II Plus Specialty Drug…Siemens Healthcare Diagnostics, Inc. · 2015
  4. Descendant · 3 generations on · 23 of its ownK161216 Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, Immunalysis…Immunalysis Corporation · 2017
  5. Descendant · 4 generations on · 19 of its ownK180427 ARK Fentanyl AssayArk Diagnostics, Inc. · 2018
  6. Descendant · 2 generations on · 18 of its ownK042988 Rapid One Step Buprenorphine Test CardTianjin New Bay Bioresearch Co., Ltd. · 2005

Showing 5 of 60 descendants. See all descendants

Descendants cleared per year

2004: 12005: 22006: 12007: 12008: 12009: 12010: 22011: 12013: 22014: 12015: 32016: 12017: 32018: 52019: 22020: 22022: 12023: 52024: 152025: 72026: 3
2004high 15 (2024) · low 0 (2012)2026

Most influential descendants

Showing 5 of 60 · See all
  • K040316Cedia Buprenorphine AssayMicrogenics Corp. · 2004 · cites it directly52descendants
  • K150606Emit II Plus Buprenorphine Assay, Emit II Plus Specialty Drug Calibrator/Control Level…Siemens Healthcare Diagnostics, Inc. · 2015 · 2 generations on25descendants
  • K161216Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, Immunalysis Fentanyl Urine…Immunalysis Corporation · 2017 · 3 generations on23descendants
  • K180427ARK Fentanyl AssayArk Diagnostics, Inc. · 2018 · 4 generations on19descendants
  • K042988Rapid One Step Buprenorphine Test CardTianjin New Bay Bioresearch Co., Ltd. · 2005 · 2 generations on18descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K001178Cedia Dau 6-Acetylmorphine AssayMicrogenics Corp.2000—
+1K040316Cedia Buprenorphine AssayMicrogenics Corp.2004—
+2K150606Emit II Plus Buprenorphine Assay, Emit II Plus Specialty Drug…Siemens Healthcare Diagnostics, Inc.2015—
+3K161216Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay, Immunalysis Fentanyl…Immunalysis Corporation2017—
+4K180427ARK Fentanyl AssayArk Diagnostics, Inc.2018—
+2K042988Rapid One Step Buprenorphine Test CardTianjin New Bay Bioresearch Co., Ltd.2005—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
200410
200520
200610
200710
200810
200910
201020
201110
201320
201410
201530
201610
201730
201850
201920
202020
202210
202350
2024150
202570
202630
FIG. 1 — Lineage of K001178, 2000–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in DJG? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new DJG device

  1. #1 K232659 Dochek® Multi-Drug Urine Test Cup Rx, Dochek®…score 17.6 · 8 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against?

FDA has not posted a summary or statement for it, so its predicates are not known.

What descends from it? (60)

See all 60

4 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K040316Cedia Buprenorphine AssayMicrogenics Corp.200452
K173183CEDIA Heroin Metabolite (6-AM) AssayMicrogenics Corporation20172
K102779Emit II PLUS6-Acetylmorphine Assay; Emit II Plus 6-AM/ Ecstasy Calibrator/ Control Level…Siemens Healthcare Diagnostics, Inc.20111
K1011956-Acetylmorphine Enzyme Immunoassay with 6-Acetylmorphine Calibrators and ControlsLin-Zhi International, Inc.20101

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K040316 (Microgenics Corp., 2004) has gone furthest, with 52 descendants of its own.

How does its category compare?

All DJG devices

DJG Enzyme Immunoassay, Opiates: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · DJG

3in 2025

2007: 22008: 22009: 22010: 62011: 62012: 52013: 52014: 92015: 122016: 22017: 42018: 52019: 32020: 52021: 32022: 22023: 102024: 52025: 32026 (partial year): 3
2007high 12 (2015) · low 2 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · DJG

31in 2025

2010: 187 days median2011: 233 days median2012: 95 days median2013: 60 days median2014: 62 days median2015: 141 days median2017: 101 days median2018: 134 days median2019: 235 days median2020: 30 days median2021: 422 days median2023: 140 days median2024: 150 days median2025: 31 days median2026 (partial year): 157 days median
2007high 422 (2021) · low 30 (2020)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · DJG

2in 2025

2011: 12019: 12025: 2
2007high 2 (2025) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · DJG

1in 2025

2011: 42012: 12013: 42015: 32016: 22017: 12018: 12021: 22022: 12024: 32025: 1
2007high 4 (2011) · low 0 (2007)2025

MAUDE reports naming product code DJG, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20082—00
20092—00
2010618700
2011623314
201259501
201356004
201496200
20151214103
20162—02
2017410101
2018513401
2019323510
202053000
2021342202
20222—01
20231014000
2024515003
202533121
202631570—
Cite this page

510(k) Report. “K001178: Cedia Dau 6-Acetylmorphine Assay.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K001178

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026